They found that: Aspirin has been associated with a reduction of 12 percent of cardiovascular events, which was not statistically significant.Most studies have evaluated the incidence of major bleeding, which is the main risk associated with aspirin. Aspirin for PAD: More study needed . continues
In PAD, fatty deposits accumulate in the lining of the arteries that send blood to all parts of the body except the heart and brain. As CAD restricts blood flow to the heart, PAD reduces blood flow to the arms, legs, feet and other major organs.
Hiatt WebMD that a process currently underway in the UK, could help to clarify the role of aspirin in patients with peripheral arterial disease.
In the new analysis of combined data from 18 randomized clinical trials with more than 5,000 patients, daily aspirin therapy was not associated with a significant reduction in heart attacks and death from heart attack or stroke.
The downside is that patients ignore these risk factors than others because they think that aspirin alone will prevent them from having a heart attack or stroke, he said. It ‘much more important that their stay on the drugs that have been shown to reduce their risk.
In the analysis published recently, Hiatt and colleagues combined data from studies comparing outcomes in patients with PAD who took aspirin in those patients who did not.
The research appears May 13 issue of the Journal of the American Medical Association. With millions PAD may benefit from aspirin
My interpretation is that there is really no reason to prescribe aspirin for these patients, but I suspect it will be a bit ‘controversial, he said. Others may doubt it.
Cardiologist and study co-author J. Mori Krantz, MD, Colorado Prevention Center, tells WebMD that a large randomized trial is needed to understand fully the risks and benefits of aspirin therapy in patients with PAD.
A new analysis raises more questions about the benefits of therapy in patients with peripheral arterial disease, a condition characterized by restricted blood flow in the arms and legs that is common in people with diabetes.
When light hits the retina of the eye, called the information in the thalamus before being sent to the visual cortex of the brain for processing. Similarly, auditory and somatosensory the information is routed through the thalamus to the cortex before leaving for the more complicated treatment.
He stressed that the 18 studies included in the analysis, 15 were published more than a decade ago. In addition, some of the studies involved a small number of patients and were of short duration, which could skew the results.
Many patients with PAD experience leg cramps during intense activity, but others have no symptoms.
Internist and researcher Mary McDermott PAD McGrae, MD, of Northwestern University’s Feinberg School of Medicine, agrees.
Although the value of aspirin in patients with PAD remains a subject of debate, Hiatt said there is no debate about the benefits of other preventive therapies like – and lower for reducing cardiovascular risk in this patient population.
But the negative results of some recent studies have questioned the benefits of aspirin therapy in patients with PAD and diabetes. Aspirin for PAD: More study needed
But he adds that it is not clear whether the benefits outweigh the risks of aspirin in approximately 4 to 6 million patients with PAD who don t have documented coronary artery disease.
The benefits of aspirin in coronary heart disease is unequivocal, but we can not say the same for patients with peripheral arterial disease, he said. In this era of evidence-based medicine, we owe it to ourselves to carefully study this regimen in this population.
The American Heart Association and American College of Cardiology recommends aspirin therapy for patients with PAD and the American Diabetes Association recommends aspirin for people with diabetes at high risk of having a heart attack or stroke.
This analysis provides a more complete picture of the benefits of aspirin in patients with peripheral arterial disease, but we need more data, McDermott WebMD.
A statistically significant , nonfatal stroke reduction occurred in the aspirin group.